LONDON (Reuters) – AstraZeneca on Thursday beat expectations for its first -quarter profit and revenue, helped by sales of some of its oncology as well as rare blood disorder drugs.
The London-listed drugmaker, which reports its results in U.S. dollars, reported adjusted profit of $1.92 per share on sales of about $10.9 billion.
Analysts on average were expecting $1.71 per share on sales of about $10.6 billion, according to company-compiled consensus estimates.
(Reporting by Natalie Grover and Maggie Fick; Editing by Tomasz Janowski)
